Goldman Sachs
INBS icon

Goldman Sachs’s Intelligent Bio Solutions INBS Stock Holding History

Goldman Sachs’s Portfolio INBS Stock Details INBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,283
Closed -$13.1K – 6617
2025
Q3 		$13.1K Hold
1,283
– – ﹤0.01% 6248
2025
Q2 		$22.1K Buy
1,283
+1
+0.1% +$14 ﹤0.01% 5972
2025
Q1 		$18.5K Buy
+1,282
New +$23.9K ﹤0.01% 5944
2022
Q2 		– Sell
-18
Closed -$33K – 6573
2022
Q1 		$33K Buy
+18
New +$41.4K ﹤0.01% 6335
2021
Q3 		– Sell
-8
Closed -$77K – 6349
2021
Q2 		$77K Buy
+8
New +$76.5K ﹤0.01% 6007

Other funds holding INBS

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CW
Curio Wealth Annapolis, Maryland $293M AUM 14.23% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's INBS Position: Q4 2025 in Review

Goldman Sachs sold out of Intelligent Bio Solutions (INBS) in Q4 2025, closing a stake of 1,283 shares — an estimated $13.1K sold.

Goldman Sachs first reported a position in INBS in Q2 2021 and held it in 5 quarters. The position peaked at $77K in Q2 2021. 7 funds tracked by Wall St. Rank hold INBS as of Q4 2025.

  • Goldman Sachs reported no remaining Intelligent Bio Solutions position as of Q4 2025 after selling out during the quarter.
  • Goldman Sachs sold 1,283 Intelligent Bio Solutions shares in Q4 2025, an estimated $13.1K.
  • Goldman Sachs first reported a position in Intelligent Bio Solutions in Q2 2021 and held it in 5 quarters.
  • Goldman Sachs's Intelligent Bio Solutions position peaked at $77K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Intelligent Bio Solutions as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.